25gaa01 10.3205/25gaa01 urn:nbn:de:0183-25gaa014 Meeting Abstract Berres Berres Judith J

Institut für Klinische Pharmakologie, Uniklinik RWTH Aachen, Aachen, Germany

jberres@ukaachen.de author Uhlig Uhlig Kathrin K

Institut für Klinische Pharmakologie, Uniklinik RWTH Aachen, Aachen, Germany

author Sommer Sommer Jakob J

Institut für Klinische Pharmakologie, Uniklinik RWTH Aachen, Aachen, Germany

author Just Just Katja S. KS Prof.

Institut für Klinische Pharmakologie, Uniklinik RWTH Aachen, Aachen, Germany

kjust@ukaachen.de author German Medical Science GMS Publishing House

Düsseldorf

610 20251111 engl This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). M0632 01 Gesellschaft für Arzneimittelanwendungsforschung und Arzneimittelepidemiologie e.V. (GAA) 32. Jahrestagung der Gesellschaft für Arzneimittelanwendungsforschung und Arzneimittelepidemiologie Abstracts Jena 20251113 20251114 25gaa01 TextBackground: The climate change causes an increasing number of hot days in Europe. Although evidence for a temperature-depending increase in adverse drug reactions exists, no concrete recommendations for dose adjustments of causative drug groups have been established to date. Likewise, no consistent definition of heat-associated symptoms exists.Materials and Methods: For identification, the multicentric ADRED trial (Adverse Drug Reactions in Emergency Departments, DRKS-ID: DRKS00008979) served as basis, containing patients with a suspected adverse drug reaction in emergency departments, symptoms and medication including WHO-UMC causality assessments of all drugs taken. The cases were linked with temperature data of Germany’s National Meteorological Service (DWD) at enrolment date and in three-day-mean before enrolment. Symptoms were visually identified using heatmaps, while relative frequency of symptoms in the group with causally accused diuretic (n = 1050) vs. not causally accused diuretic (n = 2330) were compared in dependence of daily maximum and mean temperature. Focus was set on summer days and hot days according to DWD (daily maximum temperature ≥ 25°C). A literature comparison was conducted for plausibility.Results: The identified symptoms included vertigo (rel. frequency in subgroup with causally accused diuretics ≥ 25°C, n = 182: 17.6%), dehydration (14.3%), syncope (12.1%), electrolyte imbalance (11.5%), hypotonia (10.4%), fall (10.4%), peripheral oedema (7.1%), vomiting (7.1%), fatigue (7.1%). They showed both a higher relative frequency in the group with causally accused diuretics and temperature-dependency, especially at summer/ hot days. The difference between various temperature parameters was negligible. No unanticipated symptoms were observed.Conclusion: The analysis showed clear association between identified symptoms and higher temperatures in real-world data and will be further used to develop recommendations for temperature-dependent dose adjustments. 0 0 0 0